目錄:MedChemExpress LLC>>生化試劑>> PTC-028 | MCE
CAS | 1782970-28-8 | 純度 | ≥98.0% |
---|---|---|---|
分子量 | 405.32 | 分子式 | C??H??F?N? |
供貨周期 | 現貨 | 規格 | 5 mg |
貨號 | HY-103696 | 應用領域 | 醫療衛生,化工,生物產業,制藥 |
MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。
CAS No. : 1782970-28-8
產品活性:PTC-028 is an orally bioavailable inhibitor of stem cell factor BMI-1 in ovarian cancer. PTC-028 selectively inhibits cancer cells whereas normal cells remain unaffected. PTC-028 downregulates BMI-1, inducing caspase-mediated apoptosis.
研究領域:Apoptosis
作用靶點:Apoptosis
In Vitro: PTC-028 (25-500 nM; 48 hours) significantly decreases CP20, OVCAR4 and OV90 epithelial ovarian cancer cells viability. However, in normal ovarian surface epithelial cells (OSE) and fallopian tube epithelial cells (FTE) cells, up to 500 nM treatment with PTC-028 for 48 hours has minimal effect (~18-30% decrease).
PTC-028 (100 nM; 2-12 hours) increases the phosphorylated BMI-1 species in a time-dependent manner. PTC-028 subsequently reduces BMI-1 in the biochemical functional readout .
uH2A is observed up to 12 h with PTC-028 (100 nM) in both CP20 and OV90 cells while total H2A levels remain unchanged .
PTC-028 (100 nM; 48 hours) decreases the expression of XIAP and RIPK1 while LC3B levels remains unchanged compared to that of the control .
Significant cleavage of Caspase 7, Caspase 9 and PARP is observed in PTC-028 (100 nM; 48 hours).
In Vivo: PTC-028 (15 mg/kg; administered orally twice weekly) causes ~94% (0.169 g) reduction in tumor weight compared to the control (average tumor weight, ~3g) .
No obvious toxicity is noted in the animals during therapy experiments as assessed by mean body weight.
PTC-028 (10 mg/kg or 20mg/kg; single oral doses) is administrated to the CD-1 mice. The Cmax is reached at both dose levels 1h post dose after which plasma concentrations slowly reduce.
相關產品:Bioactive Compound Library Plus | Apoptosis Compound Library | Anti-Cancer Compound Library | Orally Active Compound Library | Targeted Diversity Library | Cancer Stem Cells Compound Library | SY-5609 | BRD4 Inhibitor-18 | 8α-Tigloyloxyhirsutinolide 13-O-acetate | AAPK-25 | Dutasteride-13C6 | Oleic acid-13C | Abacavir sulfate | Meloxicam-d3-1 | Thailanstatin D | SB-218078 | Toyocamycin | Sorafenib-d4 | Busulfan | Dinaciclib | CR-1-31-B | 142I5 | Farudodstat | Ecteinascidin 770 | AT9283 | Staurosporine | SNS-032 | AZA1 | Bleomycin A5 | Xevinapant | Mangiferin | Cambinol | hGGPPS-IN-1 | Bafetinib | Dinoprost-d4
熱門產品線:重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
• 產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業技術服務;
• 設有專業的實驗中心和嚴格的質控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
• 產品的生物活性多經各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業團隊跟蹤最新的制藥及生命科學研究進展,為您提供*新的活性化合物;
• 與世界各大制藥公司及著名科研機構建立了長期的合作。